Inactive Instrument

Highlights Novartis CBOE EUROPE EQUITIES

Equities

0QLR

CH0012005267

End-of-day quote CBOE EUROPE EQUITIES Other stock markets
- ^EUR	-

07/06	Abu Dhabi, Novartis to Collaborate on Genomics Research for Cancer Therapy	MT
07/06	Novartis, Roche's Genentech Among Companies Facing Italian Competition Watchdog Inquiry Over Eye Drug	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Abu Dhabi, Novartis to Collaborate on Genomics Research for Cancer Therapy	07/06	MT
Novartis, Roche's Genentech Among Companies Facing Italian Competition Watchdog Inquiry Over Eye Drug	07/06	MT
Novartis and others face Italy antitrust probe over eye drug	06/06	RE
Cytokinetics CEO Says Board Would Have Backed Actionable Buyout	05/06	DJ
NOVARTIS : UBS reiterates buy recommendation after ASCO	03/06	CF
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	02/06	RE
European Equities Close Higher in Friday Trading; Flash Euro Area Inflation Rises More Than Expected	31/05	MT
Swiss Market Index in the Green Amid US Rate Cut Optimism	31/05	MT
Novartis Says Late-Stage Scemblix Trial Meets Primary Endpoints	31/05	MT
Novartis Says New Data Show Long-term Efficacy, Safety of Potential Urticaria Therapy	31/05	MT
Novartis Blood Cancer Drug Scemblix Meets Main Goals of Late-stage Study	31/05	MT
Novartis: positive trial results in chronic myeloid leukemia	31/05	CF
Novartis Blood Cancer Drug Scemblix Meets Main Goals of Late-stage Study	31/05	MT
Novartis Presents Positive Results from the Pivotal Phase III ASC4FIRST Trial	31/05	CI
Novartis: efficacy of remibrutinib in urticaria -USC	31/05	CF
Novartis' Chronic Spontaneous Urticaria Treatment Shows Long-term Efficacy in Late-stage Trial Data	31/05	MT
Novartis Phase III Data Confirms Sustained Efficacy and Long-Term Safety of Oral Remibrutinib in Chronic Spontaneous Urticaria	31/05	CI
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria	31/05	DJ
Alembic Pharmaceuticals Gets US FDA Final Nod for Sacubitril and Valsartan Tablets	30/05	MT
Novartis: positive phase III results in C3G	27/05	CF